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Alzheimer Disease (AD) is difficult to diagnose by using genetic testing or other traditional 
methods. Unlike diseases with simple genetic risk components, there exists no single 
marker determining as to whether someone will develop AD. Furthermore, AD is highly 
heterogeneous and different subgroups of individuals develop the disease due to differing 
factors. Traditional diagnostic methods using perceivable cognitive deficiencies are often 
too little too late due to the brain having suffered damage from decades of disease 
progression. In order to observe AD at early stages prior to the observation of cognitive 
deficiencies, biomarkers with greater accuracy are required. By using the non-scalar, 
bidirectional correlation measure, Duo, we overcame the problem of AD’s heterogeneity 
by creating a bidirectional network. By using this method, we identified key communities 
of synchronized proteins that are significantly associated with AD. We found that low 
levels of IP10 and MIG in the cerebrospinal fluid (CSF) may be a protective factor, whereas 
high values in the CSF appeared as a risk factor. High levels of Clusterin and Sortilin are 
also found to be risk factors in the cerebrospinal fluid. Additionally, low levels of 
Testosterone, FSH and LH in the blood plasma show a protective factor in men, whereas 
high levels of GH, LH, and FSH exhibit a risk factor in women. With these initial findings 
from a cohort of individuals, we seek to replicate the process on independent datasets, 
ultimately facilitating the development of methods for revealing preclinical AD and to 
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Chapter 1: Introduction 
Alzheimer Disease1 (AD), the most common cause of dementia. It is a chronic 
neurodegenerative condition in which patients commonly experience loss of memory, 
linguistic ability, coordination, and can also experience behavioral symptoms as well 
(Alzheimers Association, 2016). While the symptoms and progression of the disease vary 
from individual to individual, the disease is progressive and worsens over time, ranging 
initially from some memory loss to severe dementia, and ultimately death (Alzheimers 
Association, 2016; Burns & Iliffe, 2009).  
 
AD is characterized by abnormal deposits of amyloid plaques and tangles in the 
brain. The plaques are defined by the presence of deposits of an insoluble protein amyloid,  
while the tangles are defined by hyper-phosphorylated tau proteins (Burns & Iliffe, 2009; 
Takahashi, Nagao, & Gouras, 2017). Initially, the patients are symptomless, though after a 
given period of time and plaque buildup, memory loss begins due to a significant amount 
of neural disconnection. As AD progresses, regions of the brain lose significant amounts 
of neurons and begin to atrophy, and the brain shrinks in size (Alzheimers Association, 
2016; National Institute on Aging, 2005). There is no known cure for AD. Current methods 
of AD treatment are procedures that increase neurotransmitters in the brain. These 
treatments have varying levels of success in patients (Alzheimers Association, 2016). 
 
                                                
1 Also known as Alzheimer’s Disease. 
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AD is the fifth leading cause of death for persons over the age of 65, and the sixth 
leading cause of death overall in the United States (Alzheimers Association, 2016; 
Kochanek, Murphy, Xu, & Tejada-Vera, 2016; Tejada-Vera, 2013). From the most recent 
National Vital Statistics Report, of the top ten causes of death in the United States, eight 
of which are disease based, AD drastically outstrips the rest in percent increase of deaths  
(Kochanek et al., 2016). Of the eight diseases in the top ten causes of death among US 
citizens, only AD and nephritis, nephrotic syndrome, and nephrosis experienced an 
increase in deaths. Nephritis, nephrotic syndrome, and nephrosis death rates increased only 
1.54%, whereas rates of death for AD increased  53.9% (Kochanek et al., 2016).  
 














                                                
2 Percent change in rates of death calculated by using the Age-Adjusted Rate of death for each year from 
National Vital Statistics Report (Kochanek et al., 2016). 
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Figure 1:  A comparison of percent change of deaths from 1999 – 2014 
  
 The cost of healthcare for persons affected by AD was 236 billion dollars in 2016, 
and has been extrapolated to cost more than 1 trillion dollars by 2050 (Alzheimers 
Association, 2016). In 2015, AD received 589 million dollars in research funding from the 
NIH, while influenza/pneumonia research, as well as nephritis, nephrotic syndrome and 
nephrosis research both received 564 million dollars in funding (National Institute of 
Health, 2016) . AD, however,  had 38,314 more deaths than influenza/pneumonia, and 
45,395 more deaths than nephritis, nephrotic syndrome, and nephrosis in 2015 (National 
Center for Health Statistics, 2016). In short, AD is a major cause of death with a rapidly 
increasing death rate and no effective treatments, yet research funding to address this 








































































































































Currently, a definitive test for AD can only come postmortem through brain tissue 
examination(National Institute on Aging, 2005). There is no single test which can diagnose 
AD, and though biomarkers with expressive power have been found, no one biomarker has 
the  diagnostic power to determine AD status  (Alzheimers Association, 2016). Though 
there are no known methods of AD diagnosis with 100% accuracy for living individuals, 
there are diagnostic tools that test memory, problem solving, and language abilities, as well 
as  brain scans(National Institute on Aging, 2005). Blood and urine tests are also taken to 
identify other potential causes to the memory loss (Alzheimers Association, 2016; National 
Institute on Aging, 2005).  
 
Imaging techniques currently in use include structural imaging, functional imaging, 
and molecular imaging (Alzheimers Association, 2016; National Institute on Aging, 2005). 
Structural imaging (e.g. CT, MRI) techniques analyze brain shrinkage by studying regions 
that tend to atrophy first (Johnson, Fox, Sperling, & Klunk, 2012). This technique, 
however, relies on brain atrophy as an indicator, and does not offer any preventative 
measure prior to this loss.  Functional imaging (e.g. fMRI) uses episodic memory tasks and 
focuses on neuronal activation within the hippocampus (Johnson et al., 2012). This method, 
while potentially effective, is extremely sensitive to head motion, and requires thorough 
performance of cognitive tasks. Molecular imaging techniques are not primarily meant for 
diagnosis, but for disease pathology (Johnson et al., 2012).  The techniques use radiotracers 
which highlight deposits of amyloid-beta, though currently cost and availability are a 
limiting factor in their use (Johnson et al., 2012).  
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Currently, a common used diagnostic tool is the Clinical Dementia Rating (CDR) 
table. CDR is an inexpensive, non-invasive measure to assess whether or not a living 
person has AD. Though the table gauges patient dementia, the rating gives strong insight 
to potential AD development (given that AD is the most common form of dementia). The 
table provides a guide for the clinician to rate the patient based on responses to a series of 
diverse interview questions obtained by an informant, typically a family member. The CDR 
calculation runs along a scale of 0 to 3, incrementing by 0.5, such that:  
Table 2: CRD Scoring 
CDR Score  Impairment 
0 Normal 
0.5 Questionable Dementia 
1 Mild Dementia 
2 Moderate Dementia 
3 Severe Dementia 
 
In these cases “questionable dementia” refers to consistent slight forgetfulness and partial 
recollection of events, while “mild dementia” includes “interference with everyday 
activities” (Alzheimers Association, 2016; Burke et al., 1988; National Institute on Aging, 
2005). Though individual informants may vary in their scoring, the overall algorithm for 
the CDR can be reliably used, particularly due to the CDR’s testing of multiple areas of 
function (Burke et al., 1988).   
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1.2 Causes  
 
There is no one specific cause to AD, as genetics, lifestyle, environment, and a host 
of other factors come into play (National Institute on Aging, 2005). The currently known 
AD pathways are extremely complex and highly integrated (M Kanehisa & Goto, 2000; 
Minoru Kanehisa, Furumichi, Tanabe, Sato, & Morishima, 2016). The high level of 
interaction within the AD pathway can be indicative of high levels of synchronized protein 
activity (i.e. the interaction of analyte A with analyte B is of a synchronous nature). No one 
of these analytes, however, can individually denote AD status.  
 
On the other hand, a similar disease phenotype, referred to as Familial Alzheimer 
Disease (FAD, also known as Early Onset Alzheimer Disease (EOAD)), arises within 
particular families and exhibits a dominant inheritance pattern. There are currently three 
known genes which play a significant role in the manifestation of FAD: Amyloid Precursor 
Protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2). Those with a specific 
mutations in APP or PSEN1 have a 100% chance to develop AD and those with a mutation 
in PSEN2 have a 95% chance to develop AD(Goldman et al., 2011; Karch & Goate, 2014). 
These mutations, however, only account for 1-5% of all known Alzheimer Disease cases 
(Alzheimers Association, 2016; Goldman et al., 2011).  Individuals with these genetic 
mutations overwhelmingly tend to develop cognitive impairment prior to the age of 65. 
The more common disease state, in which symptoms develop after age 65 is thus classified 
as Late Onset Alzheimer Disease (Alzheimers Association, 2016), and this condition is 
referred to as simply ‘AD’ throughout the rest of this thesis.  
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In AD patients, there are three identified main risk factors: age, family history, and 
a particular genetic variant, apolipoprotein E (APOE) 𝜀4 gene (Alzheimers Association, 
2016).  While increasing age plays a growing role in the development of AD, genetics play 
a strong role and it is estimated that AD has heritability rate of 0.7 (Goldman et al., 2011). 
Of particular importance is the number of APOE	𝜀4 alleles possessed by the 
individual(Goldman et al., 2011; Liu, Liu, Kanekiyo, Xu, & Bu, 2013). However, rates of 
AD development with 𝐴𝑃𝑂𝐸𝜀4 vary among homozygous  and heterozygous status, as well 
as age and gender (Goldman et al., 2011; Liu et al., 2013). Individuals with a family history 
of AD have an increased likelihood of AD development which is not exclusively described 
by 𝐴𝑃𝑂𝐸𝜀4 inheritance (Alzheimers Association, 2016). 
 
No single one of the above genetic variants in APP, PSEN1, PSEN2, or APOE has 
individually been indicative of whether or not one will develop AD. Consequently, the use 
of biomarkers is being explored as a means to accurately identify presymptomatic AD. 
While hundreds of biomarkers have been collected for LOAD cases and controls, to date 
no single biomarker has provided accurate prediction of disease state. What we can do, 





 A network can be thought of as a graph with nodes and edges. An edge between 
any two nodes illustrates some relationship between the two nodes. Networks can be 
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modeled in any number of ways, where nodes and edges can denote cities with 
interconnected roadways, friends on a social media site with mutual friendships, genes with 
shared genetic pathways, genes/proteins with correlated levels of expression, etc. 
(Batushansky, Toubiana, & Fait, 2016; Langfelder & Horvath, 2008). 
Edges within a network can demonstrate numerous types of relationships. Edges 
may be weighted or unweighted, where the weight can denote a measurement of 
connection. Edges can also be directed or undirected, where a directed edge illustrates a 
connection from node X to node Y, but not from node Y to node X.  An example of an 
unweighted network is one denoting mutual friends via social media (Figure 2). Each node 
represents a friend of the author on Facebook, and each edge represents a Facebook 
friendship between those friends.  
 
Figure 2: A network of mutual Facebook friends 
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The edges between each node offer some measure of relation. In unweighted networks, a 
higher degree of correlation can be denoted by a greater amount of adjacent nodes, while  
in weighted networks, correlation of nodes can be denoted by edge weights, which can be  
determined by some correlation measure (Batushansky et al., 2016). By paring out lesser 
correlated edges in a weighted network, sub-networks, also known as modules or 
communities, can be more easily observed (Figure 3). 
 
 
Figure 3:  A Progression of edge paring based on edge weight 
 
 
 In biostatistical networks, differing methods of modeling have come into play. In 
many networks, nodes act as  genes or proteins while the edges between offer some 
measures of correlation (typically a weighted network) (Batushansky et al., 2016; 
Langfelder & Horvath, 2008). Some methods of modeling use a single gene as a node to 
act as a delegate for other genes in its community, known as an eigengene, to compute a 
“meta-analysis” to determine potential correlations between entire communities 
(Langfelder & Horvath, 2008). Other methods look for entire communities of correlated 
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genes (Climer 2017). For many of these complex models, a method of correlation between 




1.4 Correlation Measures 
 
Traditional correlation measures such as Pearson’s Correlation Coefficient (PCC) 
look for a linear correlation between two variables A and B (equation 1).   
 
𝑝),+ = 	 𝑐𝑜𝑣(𝐴, 𝐵)𝜎)𝜎+  
Equation 1: Pearson's Correlation Coefficient 
 
 
While powerful, these linear measures do not accurately account for heterogeneity as they 
return a scalar value that evaluates the entire population as a whole.  On the other hand, the 
new, vector based correlation measure, Duo, does account for heterogeneity, and facilitates 
observations of  more subtle trends in the data (Climer 2017). In Figure 4, the comparison 
between the absolute value of PCC and Duo is shown in a toy problem comprised of 10 
individuals (Climer 2017). Treating high levels (↑) as 1, low levels (↓) as -1, and neutral 
levels (–) as 0, the absolute value of PCC is = 0.45 (Climer 2017). Duo, instead, is a vector-
based correlation measure comprised of 4 separate values, which represent each 
combination, ↑-↑, ↑-↓, ↓-↑, and ↓-↓. The ↑-↓ combination yields a high correlation value of 




Figure 4: A comparison between Pearson and Duo correlation measures 
 
 
 Duo excels with highly heterogeneous data by increasing the networking 
scaffolding (Climer 2017). In a normal network with nodes A and B, only one edge with a 
scalar correlation would connect the two nodes. Duo however, separates the nodes into 





Traditional correlation network with nodes 
A and B 
Duo correlation network with nodes A (high), B (high), A (low), and 
B (low) 
Figure 5: Comparison between a traditional correlation network and a Duo correlation network 
 
A B A B
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In using Duo, we increase our network scaffolding, and create networks that address 
heterogeneity while retaining more detailed information about the nature of identified 
correlations, which allow for the potential finding of previously overlooked communities.   
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Chapter 2: Methodology 
2.1 The Data 
 
All participants and family members provided written informed consent (Deming 
et al., 2016). Individual samples came from Washington University (WU), Alzheimer’s 
Disease Neuroimaging Initiative (ADNI). Protein levels were analyzed from two distinct 
tissues: CSF and Blood Plasma.  
 
Both tissue datasets include gender (where gender 1 is male, and gender 2 is 
female), age, two CDR scores (the subject’s initial and last scores), APOE genotype, ptau 
levels, protein data, and log transformed protein data standardized such that the mean for 
each protein was equal to zero (Deming et al., 2016). The initial data include:  
 
 CSF Blood Plasma 
Number of Individuals 673 818 
Number of Proteins / 
Analytes 
52 146 
Average Age 75.03 76.36 
Highest Age 93.00 95.00 
Lowest Age 48.82 48.82 
 
The CSF and Blood Plasma sets have 536 overlapping individuals.  
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2.2 Data Cleaning  
 
The log transformed protein data for both tissues were rescaled into the range  [-1, 
1] with equation 2, where x is an individual protein, and 𝑿 is set of proteins of that type 
across all individuals:  𝐹 𝑥 = 	2 :	;<=>	(𝑿)<?@ 𝑿 ;<=>	(𝑿) + 1 
Equation 2: Rescaling to [-1, 1] 
  
 
Rescaling from -1 to 1 can produce unexpected results when outliers are present (e.g. 
Figure 6) so such outliers were removed. A total of 2 outlier values were removed in the 
CSF dataset and 60 outlier values from the Blood Plasma set. Also, individuals or proteins 
with greater than 10% missing data were then removed from the testing set.   
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2.3 Determining Cases, Controls, and Other Scenarios 
 
Case/control status is based on the individual’s two CDR scores. Due to the 
progressive nature of Alzheimer Disease, any individuals with non-zero initial scores and 
final CDR scores of zero were removed (14 individuals removed from CSF, 13 from Blood 
Plasma).  Because we are focusing on Late Onset Alzheimer Disease , all individuals below 
the age of 65 with CDR scores of zero were also removed (31 individuals removed from 
CSF, 23 from Blood Plasma).  
 
Because there may exist some minimal variances in CDR ratings among raters-in-
training, experienced raters, and clinicians, and due to potential ambiguity of a CDR score 
of 0.5, we split the data into two scenarios in order to accommodate for possible (yet 
improbable) differences among the data (Tractenberg, Schafer, & Morris, 2001).  
 
For both scenarios, all individuals with zero scores for both their initial and final 
CDR ratings were labeled as controls.  Individuals with a CDR score greater than or equal 
to one were labeled as cases. We employed two scenarios and the status of the remaining 
individuals varies depending on the scenario.  
Table 3: General Case/Control Format 
Initial CDR Final CDR Status 
0 0 Control 
0 Non-Zero Case 
Non-Zero Non-Zero Case 




For Scenario 1, all individuals with a last CDR of 0.5 were removed. Controls are 
all individuals with a CDR progression of 0 to 0 and are over the age of 65. Cases are all 
individuals with CDR progressions ending with a final CDR greater than or equal to 1.  
Table 4: Scenario 1 Case/Control Format 
Initial CDR Final CDR Status 
0 0 Control 
0 1 or Greater Case 
Non-Zero 1 or Greater Case 
Non-Zero 0 Removed 
Non-Zero 0.5 Removed 
 
Scenario 2 
This scenario includes all CDR progressions ending with a non-zero CDR score as 
cases. The controls are the same as scenario 1 (i.e. CDR progression of 0 to 0 over the age 
of 65).  
Table 5: Scenario 2 Case/Control Format 
Initial CDR Final CDR Status 
0 0 Control 
0 0.5 or Greater Case 
Non-Zero 0.5 or Greater Case 
Non-Zero 0 Removed 
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Scenarios were additionally split by sex to explore gender-specific differences in 
protein concentration3. 
 
Table 6 : Dataset Populations 
Dataset Scenario Gender Cases Controls 
CSF Scenario 1 All  198 266 
Gender 1  106 106 
Gender 2 92 159 
Scenario 2 All  357 266 
Gender 1 202 106 
Gender 2 155 159 
Plasma Scenario 1 All 297 212 
Gender 1  164 81 
Gender 2 133 131 
Scenario 2 All  568 213 
Gender 1 336 82 
Gender 2 232 131 
Intersection Scenario 1 All  181 192 
Gender 1  97 71 
Gender 2 84 121 
Scenario 2 All  314 192 
Gender 1 179 71 
Gender 2 135 121 
 
  
                                                





Duo requires the discretization of expression values into ‘high’, ‘neutral’, and ‘low’ 
categories. We determined to test two separate quantiles for these classifications. The first, 
more conservative quantile, considers the upper and lower quartiles (25%) to be considered 
high and low values (while the center 50% is neutral), while the second, more liberal 
method considers the upper and lower tertile (33%) to be considered high and low, 
respectively, with the center 34% remaining neutral. The thresholds for high and low were 
determined across all protein data.  
 
 





Table 7 : Dataset Quantile Thresholds 
Dataset Network Boundary Quartile Tertile 
CSF Whole Upper  0.195873 0.128979 
Lower -0.197192 -0.127014 
Gender 1  Upper  0.232917 0.163484 
Lower -0.152428 -0.084227 
Gender 2 Upper  0.160964 0.0907704 
Lower -0.240696 -0.164465 
Blood Plasma Whole Upper  0.185038 0.118496 
Lower -0.18508 -0.12005 
Gender 1  Upper  0.176252 0.111341 
Lower -0.191848 -0.125886 
Gender 2 Upper  0.196283 0.127695 




Whole Upper 0.186376 0.121853 
Lower -0.183821 -0.118061 
Gender 1 Upper  0.185934 0.122612 
Lower -0.180545 -0.115381 
Gender 2 Upper  0.18706 0.120862 
Lower -0.188136 -0.121588 
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2.5 Permutation Testing 
 
To determine an accurate threshold for identifying significant correlations, we ran 
permutation tests on cleaned data, where the protein values were scrambled across the 
population’s individuals. These permutation trials preserve the mean, standard deviation, 
and all other statistical properties for each protein while destroying inherent correlations 
between pairs of proteins. Permutation tests were run 1000 times for each candidate 
threshold. Duo thresholds were conservatively chosen such that there was zero false edges 
between any pair of nodes for any the 1000 trials. This strategy makes it highly unlikely 
that any false-positive edge will appear in the constructed network. The conservative Duo 
thresholds for the dataset are4: 
Table 8:  Initial Duo Thresholds 
 Quantile Gender Initial Duo 
Threshold 
CSF  0.25 Entire Population 0.35 
Gender 1  0.40 
Gender 2 0.40 
0.33 Entire Population 0.45 
Gender 1  0.45 
Gender 2 0.50 
Plasma 0.25 Entire Population 0.35 
Gender 1  0.50 
Gender 2 0.50 
0.33 Entire Population 0.425 
Gender 1  0.55 
Gender 2 0.525 
                                                
4 The gender values start at a higher threshold. This is most likely due to smaller sample sizes.  
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Intersection  0.25 Entire Population 0.425 
Gender 1  0.525 
Gender 2 0.525 
0.33 Entire Population 0.50 
Gender 1  0.575 




 2.6 Duo 
 
With proper Duo thresholds in hand, we then created networks of correlated nodes. 
During the computation of Duo correlations for the construction of the networks, all 
individuals were included, without any case/control labeling. The basic idea is to identify 
patterns of proteins with correlated expression without bias, then check each identified 
pattern for association with AD status. We started with each of the initial Duo thresholds 
listed above. In order to further break apart super-communities, we created networks with 
incrementally (0.025) increasing Duo thresholds. In doing so, we pared down the less 
correlated nodes, while keeping those that were more highly correlated (e.g. Figure 8).  
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Figure 8: Full Network (left) Vs Subnetworks within the Full Network (right). In this illustration, 





In order to find which proteins were in the highly correlated communities within 
the network, we performed a series of breadth first searches from each node to find each 
subnetwork community of correlated nodes (Figure 9).  
 
 
     





2.7 Network Testing 
 
After finding the subnetwork communities from the breadth first search, each 
network was tested against cases and controls, according to each specific scenario. In order 
to find which communities have statistical significance, we calculated an odds ratio, 𝞞, 
between the cases and controls, such that:  	
Ο = 	 𝐶𝑎𝑠𝑒𝑠I		×	𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠O𝐶𝑎𝑠𝑒𝑠O×	𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠I  
Equation 3: Calculation for Odds Ratio 
 
where Cases𝞟 and Controls𝞟 are the numbers of cases and controls, respectively, 
possessing the entire protein pattern represented by the community and Cases𝞜 and 
Controls𝞜 are the numbers that do not possess the entire pattern.  With the odds ratio having 
been calculated, the upper and lower 95% confidence intervals were found with:   
95%	𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 = 𝑒X> YZ 	±\.^_	×	 \`abcbde \`fghifjb𝞜e \`abcbke \`fghifjbk 
Equation 4: Confidence Interval Calculation 
 
Communities with a 95% confidence interval that lie entirely above or entirely below 1.0 
were considered statistically significant.  
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Chapter 3: Results 
When running the algorithms above on each of the datasets, there emerged two 
distinct sets as expected: CSF and Plasma. The intersection data yielded no significant 
crossover between the two sets. To note, the intersection did yield the same results as below 
with additional communities of a single protein appearing in both tissues (e.g. ProinsCSF and 
ProinsPlasma).  
    Each community below displays its members, each with the direction of 
expression that exhibited the correlation, and an indicator of whether the community 
suggests a risk or protective factor for the individuals. The network from which each 
community arose with its corresponding quantile thresholds, scenarios, and minimum Duo 
thresholds are also noted. The communities denoted below are those in which the 
community displayed a significant odds ratio as defined by the 95% confidence interval. 
The Percent in Population column refers to the frequency of individuals in the population 
who express the community’s protein levels, e.g. 𝑃(𝐴 ∩ 𝐵 ∩ 𝐶 ∩ 𝐷), whereas the Percent 
Independence column refers to the probability that  the community would be expressed 
given that all proteins in that community were independent, e.g.  𝑃 𝐴 ∩ 𝑃(𝐵) ∩ 𝑃(𝐶) ∩𝑃(𝐷).  Visualizations of each network at differing thresholds, and additional data for each 










3.1 CSF Results 
 
Table 9: CSF Significant Communities 















SAP	 High	 Controls:	9.7%	 0.3%	
TBG	 High	
A2Macro	 High	




FABP	 High	 Controls:	12.6%	 0.2%	
TFF3	 High	 		 	
TNFR2	 High	 		 	
vWF	 High	 	 	
A2Macro	 Low	
Protective	 Whole		 0.33	 2	 0.55	
Cases:	8.8%	 0.4%	
FABP	 Low	 Controls:	15.3%	 0.8%	
TFF3	 Low	 	 	
TNFR2	 Low	 	 	
vWF	 Low	 	 	
ACE	 Low	
Protective	 Gender1	 0.33	 2	 0.55	
Cases:	15.1%	 3.7%	
S100B	 Low	 Controls:	24.5%	 7.3%	
Sortil	 Low	 	 	
ACE	 Low	
Protective	 Gender	1	 0.25	 2	 0.45	
Cases:	13.5%	 7.2%	
Sortil	 Low	 Controls:	24.5%	 13.2%	
Adipo Low	
Risk Gender 1 0.33 1	
	 	 	
AAT Low	 	 	 	
A1Micro Low	 0.525	 Cases:	12.7%	 0.1%	
ApoA1 Low	 0.55	 Controls:	3.9%	 0.1%	
ApoC3 Low	 	 	 	
C3 Low 	 	 	
















CLU	 High Controls:	8.9%	 2.0%	




Risk	 Whole		 0.25	 1	 0.45	
Cases:	20.2%	 9.5%	















VCAM1	 High Controls:	5.7%	 0.8%	
CLU	 High 
Risk Gender	1	 0.33	 2	
0.55	 Cases:	32.0%	 16.1%	



























































		 		 Controls:		16.2%	 7.0%	
S100B	 Low	
Protective	 Gender	1	 0.33	 1	 0.575	
Cases:		18.3%	 8.3%	















































3.2 Plasma Results 
  
Table 10: Plasma Significant Communities 







Adipo	 Low	 Protective	 Gender	1	 0.25	 2	 0.5	
Cases:	18.5%	 13.5%	
	 	
ApoA1	 Low	 		 		 		 		 0.525	 Controls:	31.7%	 21.3%		 	
‘ApoA2	 Low	 Risk	 Whole	 0.33	 1	 0.45	 Cases:	14.1%	 2.8%		 	
ApoC1	 Low	 		 		 		 		 		 	Controls:	8%	 2.4%		 	
ApoC2	 Low	 		 		 		 2	 0.45	 Cases:	15.2%	 3.9%	Controls:	8.5%	 2.5%	
BDNF	 Low	 Risk	 Whole	 0.33	 1	 0.55	 Cases:	9.9%	 0.0003%	
CD40L	 Low	 		 		 		 		 		 	 	
EGF	 Low	 		 		 		 		 		 		 	
ENA78	 Low	 		 		 		 		 		 Controls:	4.1%	 0.001%	
GROa	 Low	 		 		 		 		 		 		 	
PDGFBB	 Low	 		 		 		 		 		 		 	
RANTES	 Low	 		 		 		 		 		 		 	
TP1	 Low	 		 		 		 2	 0.55	 	Cases:	9.8%	 0.0003%	Controls:	4.1%	 0.001%	
C3	 Low	 Risk	 Gender	2	 0.33	 1	 525	 Cases:	20.3%	 8.2%	Controls:	8.4%	 2.3%	
CRP	 Low	 		 		 		 		 		 	Cases:	19.4%	 7.6%	
SAP	 Low	 		 		 		 2	 525	 Controls:	8.4%	 2.3%	
BMP6		 Low	 Protective	 Whole	 0.25	 1	 0.35	 Cases:	2.4%	 0.3%	
CNTF	 Low	 		 		 		 		 		 	 	
FASL	 Low	 		 		 		 		 		 	Controls:	7.5%	 0.5%	
MCP3	 Low	 		 		 		 		 		 		
	
CFHR1	 High	 Protective	 Whole	 0.33	 1	 0.45	 Cases:	12%	 5.2%	
Vitron	 High	 		 		 		 		 		 Controls:	18.9%	 7.8%	
ProteinS	 High	 		 		 		 2	 0.45	 Cases:	12.2%	 4.8%	Controls:	18.9%	 7.7%	
CPEP	 High	 Risk	 Whole	 0.33	 1	 0.45	 Cases:	19%		 1.4%		 	
Insulin	 High	 		 		 		 		 0.475	 		 		 	
Proins	 High	 		 		 		 		 0.5	 Controls	12%	 0.7%		 	
Proinst	 High	 		 		 		 		 0.525	 		 		 	
FSH	 High	 Risk	 Gender	2	 0.25	 1	 0.55	 Cases:	77.4%	 73.7%		 	
LH	 High	 		 		 		 		 0.575	 Controls:	55.7%	 43.6%		 	
		 		 		 		 		 2	 0.55	 Cases:	74.6%	 68.4%	
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		 		 		 		 		 		 0.575	
Controls:	55.7%	 43.6%	
	 	
FSH	 Low	 Protective	 Gender	1	 0.25	 1	 0.575	 Cases:		54.7%	 42.1%	Controls	71.6%	 63.2%	
LH	 Low	 		 		 		 2	 0.575	 Cases:	51.4%	 38.1%	Controls:	72%	 63.7%	
		 		 		 		 0.33 1	 0.6	 Cases:	63.4%	 52%	Controls:	81.5%	 72.6%	
		 		 		 		 	 2	 0.6	
Cases:		63.4%	 49.2%	
Controls:	81.7%	 72.8%	
FSH	 High	 Risk	 Gender	2	 0.25	 1	 0.525	 Cases:	42.9%	 38.3%	
LH	 High	 		 		 		 		 		 Controls:	28.5%	 19.3%	
GH	 High	 		 		 		 		 		 		 	
FSH	 Low	 Protective	 Gender	1	 0.25	 1	 0.525	 Cases:	42.2%	 29.3%		 	
LH	 Low	 		 		 		 		 0.55	 Controls:	60.5%	 52.3%		 	
Testosterone	 High	 		 		 		 2	 0.525	 Cases:	39%	 25.5%		 	
		 		 		 		 		 		 0.55	
Controls:	61%	 52.8%	
	 	
		 		 		 		 0.33 1	 0.55	
Cases:	53.4%	 41.6%	
	 	
		 		 		 		   		 0.575	
Controls:	77.8%		 67.2%	
	 	
		 		 		 		   2	 0.55	
Cases:	52.3%	 39.2%	
	 	
		 		 		 		   		 0.575	
Controls:	78%	 69.5%	
	 	
FSH	 High	 Risk	 Whole	 0.25	 1	 0.45	 Cases:		22%	 4.7%		 	
LH	 High	 		 		 		 		 0.475	 Controls:	13.9%		 13.9%		 	
Testosterone	 Low	 		 Gender	2	 0.33	 1	 0.575	 Cases:	69%	 61.2%	Controls:	40.9%	 33.8%	
		 		 		 		 		 2	 0.575	
Cases:	66.4%	 57.5%	
Controls:	40.9	 40.9%	
MMP9	 High	 Risk	 Whole	Network	 0.25	 1	 0.35	
Cases:	24.1%	 9.0%	
	 	
MMP9tot	 High	 		 		 		 		 0.375	 		 		 	
		 		 		 		 		 		 0.4	
		 	
	 	
		 		 		 		 		 		 0.425	
Controls:	12.0%	 3.2%	
	 	
		 		 		 		 		 		 0.45	
		 	
	 	
		 		 		 		 		 		 0.475	
		 	
	 	
		 		 		 		 		 2	 0.35	
Cases:	21.6%	 7.5%	
	 	
		 		 		 		 		 		 0.375	
		 	
	 	
		 		 		 		 		 		 0.4	
		 	
	 	
		 		 		 		 		 		 0.425	 Controls:	12.0%	 3.2%	
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		 		 		 		 		 		 0.45	
		 	
	 	
		 		 		 		 		 		 0.475	
		 	
	 	
		 		 		 		 0.33	 1	 0.45	
Cases:	31.8%		 15.0%	
	 	
		 		 		 		 		 		 0.475	
		 	
	 	
		 		 		 		 		 		 0.5	
		 	
	 	
		 		 		 		 		 		 0.52	
Controls:	19.7%	 7.1%	
	 	
		 		 		 		 		 		 0.55	
		 	
	 	
		 		 		 		 		 		 0.575	
		 	
	 	
		 		 		 		 		 2	 0.45	
Cases:	29.3%	 13.3%	
	 	
		 		 		 		 		 		 0.475	
		 	
	 	
		 		 		 		 		 		 0.5	
		 	
	 	
		 		 		 		 		 		 0.52	
Controls:	19.7%	 7.1%	
	 	
		 		 		 		 		 		 0.55	
		 	
	 	
		 		 		 		 		 		 0.575	
		 	
	 	




0.5	 Cases:	25.6%	 9.9%		 	
		 		














		 		 		 2	 0.5	 Cases:	21.7%	 7.7%	
		
		
		 		 		 		 		 	
		






NTproBNP	 High	 Risk	 Whole	 0.33	 1	 0.425	 Cases:		26%	 17.8%	Controls:	9.1%	 6.0%	
MMP2	 High	 		 		 		 2	 0.425	 Cases:		22.9%	 16.8%	Controls:		9.1%	 5.9%	
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Figure 11: A visualization of shared proteins throughout the plasma findings. 
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Chapter 4: Discussion 
Of all the analyses run, 15 out of 21 communities existed in both scenarios 1 and 2. 
Even more intriguing is that 18 of the 21 communities have a community present in 
scenario 1, while scenario 2 defines only 3 out of the 21 total communities.  The majority 
of the communities exist within the more conservative realms of CDR usage (i.e. the 
quantile for high and low were the top and bottom 25%). As shown from Figures 10 and 
11, a number of communities experienced some overlap with other communities, which is 
expected because of the paring nature of the algorithm. Most communities displayed nearly 
double the level of dependence than their independence test frequencies.  Following is a 
brief discussion of proteins in the key communities identified.  
4.1 CSF 
IP10 & MIG 
Higher levels of IP10, also known as CXC motif chemokine 10 (CXC10) have been 
observed in patients with AD (Galimberti, D., Schoonenboom, N., Scarpini, E., & 
Scheltens, P., 2003).  MIG also known as Chemokine ligand 9 (CXCL9). Interestingly, 
MIG and IP10 both bind to a common receptor, CXCR3, which, while not independently 
replicated, remains a strong contender for a number of neuroimmune diseases (Müller, 
Carter, Hofer, & Campbell, 2010).  Given that low levels of IP10 and MIG are seen as a 
protective factors, while not surprising,  further solidifies that notably high IP10 and MIG 





CLU & Sortil 
Clusterin (Apo-J, CLU) interacts with a number of molecules, but most notably 
interacts with amyloid proteins, and can act as a “cytoprotective chaperone-like molecule” 
(S. E. Jones & Jomary, 2002). High levels of clusterin in CSF have been significantly 
correlated with AD (Calero et al., 2000). Sortilin binds with the sortilin related receptor L 
(SORL1), and traffics vesicles throughout the cell (Karch & Goate, 2014). SORL1 deals 
not only with reuptake and recycling in pathways, but also binds APOE-containing 
particles (Karch & Goate, 2014). High levels of sortilin in CSF, then, not properly binding 
to the SORL1, could be potentially indicative of improper cleaving of APP (Karch & 
Goate, 2014). Although there does not appear to be any literature suggesting a direct link 
between sortilin and clusterin, there does exist some connection between them in these 
results. As shown in Table 9, clusterin and sortilin express together with a frequency of 
nearly double what would be expected if they were independent, suggesting that clusterin 
and sortilin do not express independently of each other.  
 
4.2 Plasma 
CPEP, Insulin, Proins, Proinst 
 Proins (Proinsulin intact) and Proinst (Proinsulin total) are the same analyte, just 
differing measurements (Deming et al., 2016). Proinsulin, with the help of CPEP (c 
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peptide), becomes insulin (A. G. Jones & Hattersley, 2013). Elevated levels of these 
molecules in blood plasma are often indicative of diabetes. Type 2 diabetes can leave an 
individual open to vascular complications. However, it is not entirely clear as to whether 
or not these complications, while linked to greater risk for AD, are involved in AD 
pathogenesis or downstream effects. The complications may  instead be attributed to  
Vascular Dementia (Exalto, Whitmer, Kappele, & Biessels, 2012).  
 
FSH, LH, GH, and Testosterone 
There is no single community with FSH (Follicle Stimulating Hormone), LH 
(Luteinizing Hormone), GH (Growth Hormone), and Testosterone. There are, however, 3 
distinct communities: The first, FSH, LH, and Testosterone (associated with gender 1), 
second FSH, LH (associated with gender 1), and the third, FSH, LH, and GH (associated 
with gender 2). FSH and LH are directly controlled by the release of GnRH (Gonadotropin 
Releasing Hormone) (Burnham & Thornton, 2015). In goldfish models, it has been 
demonstrated that GnRH injections induce higher levels of GH in female goldfish 
(Marchant, Marchant, Nahorniak, & Peter, 1989). When GnRH stimulates the release of 
LH, LH stimulates the production of androgens (testosterone) in men and estrogens in 
women.  The release of sex hormones feeds back and disables the production of GnRH 
(Burnham & Thornton, 2015). Gonadotropins, such as LH and FSH, in high concentrations 
are thought to play a role in the production of amyloid-b plaques (Carcaillon et al., 2014; 
Short, Bowen, O’Brien, & Graff-Radford, 2001). From that, we can see the patterns 
described above in the communities, where the first community has low levels of FSH and 
 35 
LH, while having high levels of testosterone, acting as a protective factor. The second 
community, when displaying high levels of FSH and LH, leads to a risk factor, while its 
display of low levels of FSH and LH result in a protective factor. In the third community 
being considered, we see high levels of FSH, LH, and GH, all of which act as a risk factor 
for gender 2.  
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Chapter 5: Conclusion 
 Determining highly correlated communities within a multivariate network can be a 
very difficult task. With Duo, however, we have shown that it can be done, and done well. 
Duo’s ability to allow for non-scalar correlations grants a significant boon to correlation 
metric search algorithms. With Duo, we were able to determine key risk and protective 
expression patterns within our networks.  
 From exploring this network we identified 21 novel communities of potential risk 
and protection, with 19 of those communities having been generated with conservative 
populations (i.e. the removal of CDR 0.5 data). With further study and more data for 
replication, we may be likely to provide further evidence of these communities’ roles in 
the pathogenesis and progression of Alzheimer Disease. In using Duo, we have uncovered 
a novel, and not yet discussed highly correlated community. Such discoveries can offer a 
glimpse into yet unknown AD disease pathways.  
Additionally, with knowledge of these communities of biomarkers, it may be 
possible to establish a more effective method of testing to alert clinicians as to whether or 
not one may be at risk for AD at a far earlier date where drug testing may be significantly 
more successful.  
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A1Micro  		 Alpha-1	Microglobulin	
A2Macro   Alpha-2	Macroglobulin	
AAT   Alpha	-1	Antitrypsin	
ACE   Angiotensin-Converting	Enzyme	
Adipo   Adiponectin	
ANG2   Angiopoetin-2	
ApoA1   Apolipoprotein	A-I	
ApoA2  Apolipoprotein	A-2	
ApoC1   Apolipoprotein	C-I	
ApoC2   Apolipoprotein	C-II	
ApoC3   Apolipoprotein	C-III	
ApoH   Apolipoprotein	H	
B2M   Beta-2	Microglobulin	
BDNF   Brain-Derived	Neurotrophic	Factor	
BMP6	 	 Bone	Morphogenetic	Protein	6	
C3   Compliment	C3	
CD40   CD	40	Antigen	
CD40L  CD	40	Ligand	
CFHR1   Complement	Factor	H	
CLU   Clusterin	
CNTF	 	 Cilliary	Neurotrophic	Factor	
CPEP   C-peptide	
CRP	 	 C-Reactive	Protein	
EGF   Epidermal	Growth	Factor	
ENA78   
Epithelial-Derived	Neutrophil-
Activating	
FABP   Fatty	Acid	Binding	Protein	-Heart	
FASL		 	 Fas	Ligand	
FSH   Follicle	Stimulating	Hormone		
GH   Growth	Hormone		
GROa   Growth	-Regulated	alpha	protein	
Insulin   Insulin	
IP10   Interferon	gamma	Induced	Protein	10		







MMP2   Matrix	Metalloproteinase-2	
MMP9   Matrix	Metalloproteinase-9	
MMP9tot   Matrix	Metalloproteinase-9	total	
NTproBNP   Brain	Natriuretic	Peptide	
PDGFBB   Platelet	Derived	Growth	Factor	BB	
Proins   Proinsulin	-	Intact	
Proinst   Proinsulin	-	Total	
ProteinS   Vitamin	K-Dependent	Protein	S	
RANTES   T-Cell	Specific	Protein	RANTES	
S100B   S100	Calcium	Binding	Protein	B	
SAP   Serum	Amyloid	P-Component	
SHBG   Sex	Hormon	Binding	Globulin	
Sortil   Sortilin	
TBG   Thyroxin	Binding	Globulin	
Testos  Testosterone	
TFF3   Trefoil	Factor	3	
TNFR2   Tumor	Necrosis	Factor	Receptor-Like	2	
TP1   Thrombosponding-1	
VCAM1   Vascular	Cell	Adhesion	Molecule	-	1	






A.1 CSF Network Visualizations 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.2 CSF Community Metrics and Synchronization Data  
A1Micro, ApoH, C3, SAP, TBG: 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.55 1 
Odds Ratio (𝞞):  1.751030 
Cases with pattern 31 (15.8%) 
Controls with pattern 25 (9.7%) 
Cases with all but one 24 
Controls with all but 
one 
24 
Cases with no pattern 165 




Protein State Cases Frequency Controls Frequency ID 
High 0.343 0.335 nlA1Micro 
High 0.374 0.305 nlApoH 
High 0.348 0.301 nlC3 
High 0.379 0.327 nlSAP 




A1Micro, ApoH, C3, SAP, TBG: 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.55 2 
Odds Ratio (𝞞):  1.832407 
Cases with pattern 58  (16.4%) 
Controls with pattern 25 (9.7%) 
Cases with all but one 43 
Controls with all but 
one 
24 
Cases with no pattern 295 





Protein State Cases Frequency Controls Frequency ID 
High 0.361 0.335 nlA1Micro 
High 0.384 0.305 nlApoH 
High 0.367 0.301 nlC3 
High 0.375 0.327 nlSAP 
High 0.375 0.271 nlTBG 
Cases Controls
 73 
A2Macro, FABP, TFF3, TNFR2, vWF: 
Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.45 2 
Odds Ratio (𝞞):  1.890655 
Cases with pattern 25  (7.1%) 
Controls with pattern 33 (12.6%) 
Cases with all but one 35 
Controls with all but 
one 
14 
Cases with no pattern 328 




Protein State Cases Frequency Controls Frequency ID 
High 0.238 0.266 nlA2Macro 
High 0.373 0.262 nlFABP 
High 0.258 0.273 nlTFF3 
High 0.325 0.285 nlTNFR2 




A2Macro, FABP, TFF3, TNFR2, vWF: 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.55 2 
Odds Ratio (𝞞):  1.880017 
Cases with pattern 31  (8.8%) 
Controls with pattern 40 (15.3%) 
Cases with all but one 43 
Controls with all but 
one 
26 
Cases with no pattern 322 




Protein State Cases Frequency Controls Frequency ID 
Low 0.345 0.406 nlA2Macro 
Low 0.297 0.402 nlFABP 
Low 0.328 0.32 nlTFF3 
Low 0.373 0.395 nlTNFR2 




ACE, S100B, Sortil 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.55 2 
Odds Ratio (𝞞):  1.830833 
Cases with pattern 30  (15.1%) 
Controls with pattern 26 (24.5%) 
Cases with all but one 32 
Controls with all but 
one 
16 
Cases with no pattern 169 




   
Protein State Cases Frequency Controls Frequency ID 
Low 0.371 0.434 nlACE 
Low 0.312 0.387 nlS100B 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.45 2 
Odds Ratio (𝞞):  2.082407 
Cases with pattern 27  (13.5%) 
Controls with pattern 26 (24.5%) 
Cases with all but one 55 
Controls with all but 
one 
25 
Cases with no pattern 173 







Protein State Cases Frequency Controls Frequency ID 
DN 0.307 0.34 nlACE 
DN 0.233 0.387 nlSortil 
Cases Controls
 77 
Adipo, AAT, A1Micro, ApoC3, C3, 
SHBG 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.525 
0.55 
1 
Odds Ratio (𝞞):  3.578652 
Cases with pattern 13  (12.7%) 
Controls with pattern 4  (3.9%) 
Cases with all but one 7 
Controls with all but 
one 
7 
Cases with no pattern 89 
Controls with no 
pattern 
98 
Protein State Cases Frequency Controls Frequency ID 
Low 0.368 0.472 nlAdipo 
Low 0.292 0.302 nlAAT 
Low 0.358 0.274 nlA1Micro 
Low 0.481 0.34 nlApoA1 
Low 0.415 0.368 nlApoC3 
Low	 0.349	 0.292	 nlC3	




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.40 1 
Odds Ratio (𝞞):  2.926108 
Cases with pattern 18  (17.1%) 
Controls with pattern 7  (6.6%) 
Cases with all but one 21 
Controls with all but 
one 
20 
Cases with no pattern 87 






Protein State Cases Frequency Controls Frequency ID 
UP 0.274 0.123 nlANG2 





Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.40 2 
Odds Ratio (𝞞):  3.085714, 
Cases with pattern 36  (17.9%) 
Controls with pattern 7  (6.6%) 
Cases with all but one 41 
Controls with all but 
one 
20 
Cases with no pattern 165 





Protein State Cases Frequency Controls Frequency ID 
UP 0.297 0.123 nlANG2 
UP 0.262 0.198 nlCD40 
Cases Controls
 80 
B2M, CLU, VCAM1 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.525 1 
Odds Ratio (𝞞):  2.463186 
Cases with pattern 20  (19.4%) 
Controls with pattern 9  (8.9%) 
Cases with all but one 12 
Controls with all but 
one 
17 
Cases with no pattern 83 





Protein State Cases Frequency Controls Frequency ID 
UP 0.292 0.217 nlB2M 
UP 0.349 0.274 nlCLU 
UP	 0.377	 0.33	 nlVCAM1	
Cases Controls
 81 
B2M, CLU, VCAM1 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.525 2 
Odds Ratio (𝞞):  3.339259 
Cases with pattern 49  (24.6%) 
Controls with pattern 9  (8.9%) 
Cases with all but one 25 
Controls with all but 
one 
17 
Cases with no pattern 150 





Protein State Cases Frequency Controls Frequency ID 
UP 0.337 0.217 nlB2M 
UP 0.386 0.274 nlCLU 




Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.45 1 
Odds Ratio (𝞞):  1.983122 
Cases with pattern 40  (20.2%) 
Controls with pattern 30 (11.3%) 
Cases with all but one 44 
Controls with all but 
one 
57 
Cases with no pattern 158 





Protein State Cases Frequency Controls Frequency ID 
UP 0.271 0.199 nlCLU 




Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.45 2 
Odds Ratio (𝞞):  2.213768 
Cases with pattern 78  (22.0%) 
Controls with pattern 30 (11.3%) 
Cases with all but one 70 
Controls with all but 
one 
57 
Cases with no pattern 276 





Protein State Cases Frequency Controls Frequency ID 
UP 0.297 0.199 nlCLU 
UP 0.336 0.24 nlSortil 
Cases Controls
 84 
CLU, Sortil, VCAM1 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.45 2 
Odds Ratio (𝞞):  3.161677 
Cases with pattern 32  (16.1%) 
Controls with pattern 6  (5.7%) 
Cases with all but one 28 
Controls with all but 
one 
7 
Cases with no pattern 167 





Protein State Cases Frequency Controls Frequency ID 
UP 0.302 0.208 nlCLU 
UP 0.292 0.17 nlSortil 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.55 
0.575 
2 
Odds Ratio (𝞞):  2.617647 
Cases with pattern 64  (32%) 
Controls with pattern 16  (15.2%) 
Cases with all but one 34 
Controls with all but 
one 
32 
Cases with no pattern 136 





Protein State Cases Frequency Controls Frequency ID 
UP 0.386 0.274 nlCLU 





Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.40 1 
Odds Ratio (𝞞):  1.863421 
Cases with pattern 22  (11.3%) 
Controls with pattern 50  (19.2%) 
Cases with all but one 43 
Controls with all but 
one 
75 
Cases with no pattern 173 





Protein State Cases Frequency Controls Frequency ID 
DN 0.206 0.303 nlIP10 




Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.40 2 
Odds Ratio (𝞞):  1.803260 
Cases with pattern 41   (11.6%) 
Controls with pattern 50  (19.2%) 
Cases with all but one 70 
Controls with all but 
one 
75 
Cases with no pattern 312 





Protein State Cases Frequency Controls Frequency ID 
DN 0.21 0.303 nlIP10 




Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.475 
0.50 
1 
Odds Ratio (𝞞):  1.865132 
Cases with pattern 32  (16.5%) 
Controls with pattern 70  (26.9%) 
Cases with all but one 58 
Controls with all but 
one 
73 
Cases with no pattern 162 





Protein State Cases Frequency Controls Frequency ID 
DN 0.308 0.376 nlIP10 





Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.475 
0.50 
2 
Odds Ratio (𝞞):  1.799123 
Cases with pattern 60  (17%) 
Controls with pattern 70  (26.9%) 
Cases with all but one 94 
Controls with all but 
one 
73 
Cases with no pattern 293 





Protein State Cases Frequency Controls Frequency ID 
DN 0.297 0.376 nlIP10 





Network Quantile Duo 
Threshold 
Scenario 




Odds Ratio (𝞞):  2.136000 
Cases with pattern 15  (14.4%) 
Controls with pattern 27  (26.5%) 
Cases with all but one 22 
Controls with all but 
one 
23 
Cases with no pattern 89 




Protein State Cases Frequency Controls Frequency ID 
DN 0.245 0.358 nlIP10 





Network Quantile Duo 
Threshold 
Scenario 




Odds Ratio (𝞞):  2.306667 
Cases with pattern 27  (13.5%) 
Controls with pattern 27  (26.5%) 
Cases with all but one 40 
Controls with all but 
one 
23 
Cases with no pattern 173 




Protein State Cases Frequency Controls Frequency ID 
DN 0.218 0.358 nlIP10 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.525 
0.55 
2 
Odds Ratio (𝞞):  2.038902 
Cases with pattern 38  (19%) 
Controls with pattern 33  (32.4%) 
Cases with all but one 51 
Controls with all but 
one 
29 
Cases with no pattern 162 





Protein State Cases Frequency Controls Frequency ID 
DN 0.317 0.396 nlIP10 





Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.475 1 
Odds Ratio (𝞞):  1.613256 
Cases with pattern 46  (23.7%) 
Controls with pattern 42  (16.2%) 
Cases with all but one 57 
Controls with all but 
one 
57 
Cases with no pattern 148 





Protein State Cases Frequency Controls Frequency ID 
UP 0.343 0.286 nlIP10 




Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.475 2 
Odds Ratio (𝞞):  1.856593 
Cases with pattern 93  (26.3%) 
Controls with pattern 42  (16.2%) 
Cases with all but one 96 
Controls with all but 
one 
57 
Cases with no pattern 260 





Protein State Cases Frequency Controls Frequency ID 
UP 0.364 0.286 nlIP10 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.575 1 
Odds Ratio (𝞞):  2.022350 
Cases with pattern 19  (18.3%) 
Controls with pattern 33  (31.1%) 
Cases with all but one 23 
Controls with all but 
one 
21 
Cases with no pattern 85 





Protein State Cases Frequency Controls Frequency ID 
DN 0.274 0.387 nlS100B 
DN 0.302 0.434 nlSortil 
Cases Controls
 96 
A.3 Plasma Network Visualizations 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.4 Plasma Community Metrics and Synchronization Data  
Adipo, ApoA1 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1  Quartile 0.5 
0.525 
2 
Odds Ratio (𝞞):  2.051843 




Cases with all but 
one 
127 
Controls with all 
but one 
22 
Cases with no 
pattern 
274 
Controls with no 
pattern 
56 
Protein State Cases Frequency Controls Frequency ID 
DN 0.31 0.451 nlAdipo 





ApoA2, ApoC1, ApoC2 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.45 1 
Odds Ratio (𝞞):  1.889273 
Cases with pattern 42  (14.1%) 
Controls with pattern 17  (8%) 
Cases with all but one 41 
Controls with all but 
one 
40 
Cases with no pattern 255 




Protein State Cases Frequency Controls Frequency ID 
DN 0.33 0.25 nlApoA2 
DN 0.253 0.344 nlApoC1 




ApoA2, ApoC1, ApoC2 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.45 2 
Odds Ratio (𝞞):  1.940972 
Cases with pattern 86  (15.2%) 
Controls with 
pattern 
18  (8.5%) 
Cases with all but 
one 
98 
Controls with all but 
one 
40 
Cases with no 
pattern 
480 




Protein State Cases Frequency Controls Frequency ID 
DN 0.366 0.254 nlApoA2 
DN 0.308 0.347 nlApoC1 
DN	 0.35	 0.282	 nlApoC3	
Cases Controls
 127 
BDNF, CD40L, EGF, ENA78, GROa, 
PDGFBB, RANTES, TP1 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.55 1 
Odds Ratio (𝞞):  2.550437 
Cases with pattern 27  (9.9%) 
Controls with pattern 7  (4.1%) 
Cases with all but one 37 
Controls with all but 
one 
25 
Cases with no pattern 245 
Controls with no 
pattern 
162 
Protein State Cases Frequency Controls Frequency ID 
DN 0.364 0.382 nlBDNF 
DN 0.387 0.344 nlCD40L 
DN	 0.387	 0.425	 nlEGF	
DN	 0.367	 0.373	 nlENA78	
DN	 0.401	 0.429	 nlGROa	
DN	 0.35	 0.349	 nlPDGFBB	
DN	 0.364	 0.453	 nlRANTES	




BDNF, CD40L, EGF, ENA78, GROa, 
PDGFBB, RANTES, TP1 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.55 2 
Odds Ratio (𝞞):  2.522619 
Cases with pattern 52  (9.8%) 
Controls with pattern 7  (4.1%) 
Cases with all but one 59 
Controls with all but 
one 
25 
Cases with no pattern 480 
Controls with no 
pattern 
163 
Protein State Cases Frequency Controls Frequency ID 
DN 0.363 0.38 nlBDNF 
DN 0.37 0.343 nlCD40L 
DN	 0.389	 0.423	 nlEGF	
DN	 0.34	 0.371	 nlENA78	
DN	 0.386	 0.432	 nlGROa	
DN	 0.327	 0.347	 nlPDGFBB	
DN	 0.359	 0.451	 nlRANTES	





BMP6, CNTF, FASL, MCP3 
Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.35 1 
Odds Ratio (𝞞):  3.776882 
Cases with pattern 6  (2.1%) 
Controls with pattern 15  (7.5%) 
Cases with all but one 26 
Controls with all but 
one 
23 
Cases with no pattern 281 





Protein State Cases Frequency Controls Frequency ID 
DN 0.256 0.25 nlBMP6 
DN 0.202 0.302 nlCNTF 
DN	 0.259	 0.264	 nlFASL	
DN	 0.236	 0.264	 nlMCP3	
Cases Controls
 130 
CFHR1, Vitron, ProteinS 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.45 1 
Odds Ratio (𝞞):  1.709612 
Cases with pattern 33  (12%) 
Controls with pattern 38  (18.9%) 
Cases with all but one 68 
Controls with all but 
one 
49 
Cases with no pattern 242 





Protein State Cases Frequency Controls Frequency ID 
UP 0.458 0.509 nlCFHR1 
UP 0.333 0.373 nlVitron 
UP	 0.343	 0.41	 nlProteinS	
Cases Controls
 131 
CFHR1, Vitron, ProteinS 
Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.45 2 
Odds Ratio (𝞞):  1.672637 
Cases with pattern 64  (12.2%) 
Controls with pattern 38  (18.9%) 
Cases with all but one 126 
Controls with all but 
one 
49 
Cases with no pattern 462 





Protein State Cases Frequency Controls Frequency ID 
UP 0.417 0.507 nlCFHR1 
UP 0.333 0.371 nlVitron 
UP	 0.345	 0.408	 nlProteinS	
Cases Controls
 132 
CPEP, Insulin, Proins, Proinst 
Network Quantile Duo 
Threshold 
Scenario 





Odds Ratio (𝞞):  1.658191 
Cases with pattern 56  (19%) 
Controls with pattern 26  (12.4%) 
Cases with all but one 22 
Controls with all but 
one 
18 
Cases with no pattern 239 
Controls with no 
pattern 
184 
Protein State Cases Frequency Controls Frequency ID 
UP 0.337 0.283 nlCpep 
UP 0.384 0.302 nlInsulin 
UP	 0.32	 0.283	 nlProins	







Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Quartile 0.55 
0.575 
1 
Odds Ratio (𝞞):  2.727854 
Cases with pattern 103 (77.4%) 
Controls with pattern 73  (55.7%) 
Cases with all but one 23 
Controls with all but 
one 
28 
Cases with no pattern 30 





Protein State Cases Frequency Controls Frequency ID 
UP 0.925 0.733 nlFSH 




Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Quartile 0.55 
0.575 
2 
Odds Ratio (𝞞):  2.329695 
Cases with pattern 173 (74.6%) 
Controls with pattern 73  (55.7%) 
Cases with all but one 39 
Controls with all but 
one 
28 
Cases with no pattern 59 






Protein State Cases Frequency Controls Frequency ID 
UP 0.892 0.733 nlFSH 







Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.575 1 
Odds Ratio (𝞞):  2.091897 
Cases with pattern 88 (54.7%) 
Controls with 
pattern 
58  (71.6%) 
Cases with all but 
one 
37 
Controls with all 
but one 
13 
Cases with no 
pattern 
73 
Controls with no 
pattern 
23 
Protein State Cases Frequency Controls Frequency ID 
DN 0.677 0.827 nlFSH 






Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.575 2 
Odds Ratio (𝞞):  2.430206 
Cases with pattern 171 (51.4%) 
Controls with pattern 59  (72%) 
Cases with all but one 74 
Controls with all but 
one 
13 
Cases with no pattern 162 





Protein State Cases Frequency Controls Frequency ID 
DN 0.667 0.829 nlFSH 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.60 1 
Odds Ratio (𝞞):  2.545098 
Cases with pattern 102 (63.4%) 
Controls with pattern 66  (81.5%) 
Cases with all but one 33 
Controls with all but 
one 
6 
Cases with no pattern 59 





Protein State Cases Frequency Controls Frequency ID 
DN 0.756 0.864 nlFSH 




Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.60 2 
Odds Ratio (𝞞):  2.753722 
Cases with pattern 206 (63.4%) 
Controls with pattern 67 (81.7%) 
Cases with all but one 60 
Controls with all but 
one 
6 
Cases with no pattern 127 





Protein State Cases Frequency Controls Frequency ID 
DN 0.744 0.866 nlFSH 
DN 0.661 0.841 nlLH 
Cases Controls
 139 
FSH, GH, LH 
Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Quartile 0.525 1 
Odds Ratio (𝞞):  1.885135 
Cases with pattern 57 (42.9%) 
Controls with pattern 37 (28.5%) 
Cases with all but one 54 
Controls with all but 
one 
46 
Cases with no pattern 76 





Protein State Cases Frequency Controls Frequency ID 
UP 0.925 0.733 nlFSH 
UP 0.519 0.443 nlGH 
UP	 0.797	 0.595	 nlLH	
Cases Controls
 140 
FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.525 
0.55 
1 
Odds Ratio (𝞞):  2.094210 
Cases with pattern 68 (42.2%) 
Controls with pattern 49 (60.5%) 
Cases with all but one 45 
Controls with all but 
one 
21 
Cases with no pattern 93 





Protein State Cases Frequency Controls Frequency ID 
DN 0.677 0.827 nlFSH 
DN 0.622 0.765 nlLH 
UP	 0.695	 0.827	 nlTestos	
Cases Controls
 141 
FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Quartile 0.525 
0.55 
2 
Odds Ratio (𝞞):  2.439904 
Cases with pattern 130 (39%) 
Controls with pattern 50 (61%) 
Cases with all but one 89 
Controls with all but 
one 
21 
Cases with no pattern 203 





Protein State Cases Frequency Controls Frequency ID 
DN 0.667 0.829 nlFSH 
DN 0.571 0.768 nlLH 





FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.55 
0.575 
1 
Odds Ratio (𝞞):  3.052325 




Cases with all but one 45 
Controls with all but 
one 
9 
Cases with no 
pattern 
75 
Controls with no 
pattern 
18 
Protein State Cases Frequency Controls Frequency ID 
DN 0.756 0.864 nlFSH 
DN 0.689 0.84 nlLH 





FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 1 Tertile 0.55 
0.575 
2 
Odds Ratio (𝞞):  3.249042 
Cases with pattern 174 (52.3%) 
Controls with pattern 64 (78%) 
Cases with all but one 81 
Controls with all but 
one 
9 
Cases with no pattern 159 





Protein State Cases Frequency Controls Frequency ID 
DN 0.744 0.866 nlFSH 
DN 0.661 0.841 nlLH 






FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Whole Quartile 0.45 
0.475 
1 
Odds Ratio (𝞞):  1.735991 
Cases with pattern 63 (22 %) 
Controls with pattern 29  (13.9%) 
Cases with all but one 60 
Controls with all but 
one 
57 
Cases with no pattern 224 





Protein State Cases Frequency Controls Frequency ID 
DN 0.273 0.241 nlTestos 
UP	 0.451	 0.458	 nlFSH	





FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Tertile 0.575 1 
Odds Ratio (𝞞):  3.217455 
Cases with pattern 87 (69 %) 
Controls with pattern 52  (40.9%) 
Cases with all but one 37 
Controls with all but one 52 
Cases with no pattern 39 
Controls with no pattern 75 
 
  
Protein State Cases Frequency Controls Frequency ID 
DN 0.722 0.58 nlTestos 
UP	 0.955	 0.794	 nlFSH	




FSH, LH, Testosterone 
Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Tertile 0.575 2 
Odds Ratio (𝞞):  2.846154 
Cases with pattern 148 (66.4 %) 
Controls with pattern 52  (40.9%) 
Cases with all but one 61 
Controls with all but one 52 
Cases with no pattern 75 




Protein State Cases Frequency Controls Frequency ID 
UP 0.931 0.794 nlFSH 
UP	 0.849	 0.733	 nlLH	




Network Quantile Duo 
Threshold 
Scenario 







Odds Ratio (𝞞):  2.327558 
Cases with pattern 69 (24.1 %) 
Controls with pattern 25  (12.0%) 
Cases with all but one 40 
Controls with all but 
one 
26 
Cases with no pattern 217 
Controls with no 
pattern 
183 
Protein State Cases Frequency Controls Frequency ID 
UP 0.3 0.156 nlMMP9 






Network Quantile Duo 
Threshold 
Scenario 







Odds Ratio (𝞞):  2.011732 
Cases with pattern 119  (21.6 %) 
Controls with pattern 25  (12.0%) 
Cases with all but one 72 
Controls with all but one 27 
Cases with no pattern 433 
Controls with no pattern 183 
Protein State Cases Frequency Controls Frequency ID 
UP 0.273 0.155 nlMMP9 





Network Quantile Duo 
Threshold 
Scenario 







Odds Ratio (𝞞):  1.900813 
Cases with pattern 91  (31.8 %) 
Controls with pattern 41  (19.7%) 
Cases with all but one 48 
Controls with all but one 31 
Cases with no pattern 195 
Controls with no pattern 167 
 
Protein State Cases Frequency Controls Frequency ID 
UP 0.374 0.259 nlMMP9 





Network Quantile Duo 
Threshold 
Scenario 







Odds Ratio (𝞞):  1.691932 
Cases with pattern 162  (29.3 %) 
Controls with pattern 41  (19.7%) 
Cases with all but one 91 
Controls with all but one 32 
Cases with no pattern 390 
Controls with no pattern 167 
 
Protein State Cases Frequency Controls Frequency ID 
UP 0.354 0.258 nlMMP9 






Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Quartile 0.50 1 
Odds Ratio (𝞞):  2.799107 
Cases with pattern 33  (25.6 %) 
Controls with pattern 14  (10.9%) 
Cases with all but one 18 
Controls with all but 
one 
20 
Cases with no pattern 96 





Protein State Cases Frequency Controls Frequency ID 
UP 0.323 0.153 nlMMP9 




Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Quartile 0.50 2 
Odds Ratio (𝞞):  2.254237 
Cases with pattern 49  (21.7 %) 
Controls with pattern 14  (10.9%) 
Cases with all but one 31 
Controls with all but 
one 
20 
Cases with no pattern 177 





Protein State Cases Frequency Controls Frequency ID 
UP 0.28 0.153 nlMMP9 




Network Quantile Duo 
Threshold 
Scenario 
Gender 2 Tertile 0.525 
0.55 
1 
Odds Ratio (𝞞):  1.906354 
Cases with pattern 38  (29.5 %) 
Controls with 
pattern 
23  (18%) 
Cases with all but 
one 
22 
Controls with all but 
one 
23 
Cases with no 
pattern 
91 





Protein State Cases Frequency Controls Frequency ID 
UP 0.361 0.252 nlMMP9 





Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.425 1 
Odds Ratio (𝞞):  3.50 
Cases with pattern 76  (26 %) 
Controls with pattern 19  (9.1%) 
Cases with all but one 99 
Controls with all but 
one 
66 
Cases with no pattern 216 





Protein State Cases Frequency Controls Frequency ID 
UP 0.431 0.231 nlNTproBNP 




Network Quantile Duo 
Threshold 
Scenario 
Whole Tertile 0.425 2 
Odds Ratio (𝞞):  2.976744, 
Cases with pattern 128  (22.9 %) 
Controls with pattern 19  (9.1%) 
Cases with all but one 209 
Controls with all but 
one 
66 
Cases with no pattern 430 





Protein State Cases Frequency Controls Frequency ID 
UP 0.423 0.23 nlNTproBNP 
UP	 0.396	 0.258	 nlMMP2	
Cases Controls
